Payment overview · 2025
General Payments
$445.42
25 reported records · 10 companies
Healthcare provider profile · identity verified
Reid M Thomas, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SEARCY, AR · NPI 1427013945
Verified facts
What the public records show
CMS Open Payments records show Reid M Thomas, MD received $445.42 in general payments during 2025 across 25 reported records.
Amgen Inc. accounted for 16.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 214 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 162 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $73.94 | 16.6% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $72.03 | 16.2% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $67.20 | 15.1% | 3 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $65.76 | 14.8% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $60.99 | 13.7% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $41.07 | 9.2% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$24.63 | 5.5% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $16.53 | 3.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.04 | 3.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $9.23 | 2.1% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $445.42 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $72.03 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $67.20 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $67.20 | 3 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $65.76 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $59.08 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $59.08 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $41.07 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $41.07 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $41.07 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $33.66 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $27.33 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $24.63 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $16.53 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.86 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.29 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.04 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.04 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $9.23 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 214 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
74 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
73 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
214 | 36 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
162 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 734 | 148 |
| Omeprazole | Omeprazole | 581 | 130 |
| Atorvastatin Calcium | Atorvastatin Calcium | 542 | 121 |
| Losartan Potassium | Losartan Potassium | 511 | 107 |
| Sertraline Hcl | Sertraline Hcl | 447 | 78 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 406 | 89 |
| Potassium Chloride | Potassium Chloride | 369 | 81 |
| Amlodipine Besylate | Amlodipine Besylate | 351 | 76 |
| Carvedilol | Carvedilol | 340 | 63 |
| Lisinopril | Lisinopril | 340 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 329 | 67 |
| Gabapentin | Gabapentin | 328 | 72 |
| Furosemide | Furosemide | 315 | 76 |
| Metformin Hcl Er | Metformin Hcl | 315 | 69 |
| Hydrochlorothiazide | Hydrochlorothiazide | 279 | 61 |
| Tamsulosin Hcl | Tamsulosin Hcl | 269 | 61 |
| Trazodone Hcl | Trazodone Hcl | 267 | 45 |
| Tramadol Hcl | Tramadol Hcl | 232 | 58 |
| Ozempic | Semaglutide | 214 | 36 |
| Glipizide | Glipizide | 186 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 185 | 32 |
| Donepezil Hcl | Donepezil Hcl | 172 | 33 |
| Cephalexin | Cephalexin | 171 | 113 |
| Metoprolol Succinate | Metoprolol Succinate | 169 | 46 |
| Clopidogrel | Clopidogrel Bisulfate | 167 | 32 |
| Allopurinol | Allopurinol | 166 | 36 |
| Eliquis | Apixaban | 162 | 25 |
| Simvastatin | Simvastatin | 157 | 42 |
| Metformin Hcl | Metformin Hcl | 152 | 42 |
| Escitalopram Oxalate | Escitalopram Oxalate | 148 | 33 |
| Spironolactone | Spironolactone | 148 | 24 |
| Temazepam | Temazepam | 144 | 25 |
| Montelukast Sodium | Montelukast Sodium | 141 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 123 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 119 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 117 | 26 |
| Atenolol | Atenolol | 116 | 28 |
| Synthroid | Levothyroxine Sodium | 110 | 21 |
| Alprazolam | Alprazolam | 108 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 108 | 23 |
| Famotidine | Famotidine | 107 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 100 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 95 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 91 | 19 |
| Clonazepam | Clonazepam | 90 | 15 |
| Azithromycin | Azithromycin | 89 | 77 |
| Hydralazine Hcl | Hydralazine Hcl | 79 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 79 | 21 |
| Finasteride | Finasteride | 77 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 76 | 22 |
| Jardiance | Empagliflozin | 74 | 18 |
| Trulicity | Dulaglutide | 73 | 13 |
| Lorazepam | Lorazepam | 72 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 72 | 45 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 64 | 24 |
| Warfarin Sodium | Warfarin Sodium | 62 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 62 | 16 |
| Meloxicam | Meloxicam | 61 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 61 | suppressed |
| Repatha Sureclick | Evolocumab | 59 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 58 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 58 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 55 | suppressed |
| Fluconazole | Fluconazole | 54 | 32 |
| Diclofenac Sodium | Diclofenac Sodium | 49 | 11 |
| Ezetimibe | Ezetimibe | 49 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 48 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 47 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 47 | suppressed |
| Sucralfate | Sucralfate | 47 | 13 |
| Cefdinir | Cefdinir | 46 | 44 |
| Humalog Kwikpen U-100 | Insulin Lispro | 46 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 46 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 45 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 44 | suppressed |
| Estradiol | Estradiol | 42 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 41 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 40 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 40 | suppressed |
| Metolazone | Metolazone | 40 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 39 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 37 | suppressed |
| Xarelto | Rivaroxaban | 37 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 35 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 34 | suppressed |
| Pregabalin | Pregabalin | 34 | suppressed |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 21 |
| Amiodarone Hcl | Amiodarone Hcl | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Bumetanide | Bumetanide | 31 | suppressed |
| Celecoxib | Celecoxib | 31 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | 11 |
| Mupirocin | Mupirocin | 31 | 18 |
| Ondansetron Odt | Ondansetron | 31 | 17 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 31 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | suppressed |
| Klor-Con M20 | Potassium Chloride | 30 | 12 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 26 |
| Famciclovir | Famciclovir | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Nystatin | Nystatin | 28 | 21 |
| Topiramate | Topiramate | 28 | suppressed |
| Glipizide Er | Glipizide | 27 | suppressed |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Rybelsus | Semaglutide | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 22 |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | suppressed |
| Prednisone | Prednisone | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 18 |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Praluent Pen | Alirocumab | 18 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 16 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 14 |
| Metronidazole | Metronidazole | 15 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Dulera | Mometasone/Formoterol | 12 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $445.42 · 25 records | Amgen Inc. | ABRYSVO, AREXVY, BREZTRI, COMIRNATY, Dexcom G6 Transmitter, EVENITY, FARXIGA, INCEPTIV, MOUNJARO, OTEZLA, Ozempic, PREVNAR 20, REPATHA, Rybelsus, TRELEGY ELLIPTA, TWIIST, VOQUEZNA, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error